<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617197</url>
  </required_header>
  <id_info>
    <org_study_id>N202009001</org_study_id>
    <nct_id>NCT04617197</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Nerve Stimulation With Frequency Specific Microcurrent Resonance Therapy for Non Specific Chronic Low Back Pain Patents: a Prospective Double Blinded, Randomized, Placebo Control Trial</brief_title>
  <official_title>Transcutaneous Electrical Nerve Stimulation With Frequency Specific Microcurrent Resonance Therapy for Non Specific Chronic Low Back Pain Patents: a Prospective Double Blinded, Randomized, Placebo Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taiwan Resonant Waves Research Corp.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcutaneous electrical nerve stimulation (TENS) is widely used for chronic pain. Recent&#xD;
      studies showed frequency-specific microcurrent (FSM) resonant therapy was safe and effective&#xD;
      in patients with non-specific chronic low back pain. However, there was no prospective,&#xD;
      double-blinded randomized controlled trial to validate the clinical applicability. The goal&#xD;
      of this trial is to verify safety and efficacy of FSM using a TENS device, Dragon Waves&#xD;
      Resonant Home Care Electronic Nerve Stimulator-DW1330,(Taiwan Resonant Waves Research Co,&#xD;
      Taiwan R.O.C), in 60 patients with non-specific low back pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies showed that frequency-specific microcurrent (FSM) resonance therapy delivered&#xD;
      by transcutaneous electrical nerve stimulation (TENS) device is safe and effective in&#xD;
      patients with non-specific low back pain. The regiment of variable-frequency combination&#xD;
      (1-10000 Hz or 1-20000 Hz), continuous use for 36-60 mins per day and 30 to 180 days per&#xD;
      session has been proven to be safe. To validate the clinical applicability of FSM by using a&#xD;
      TENS device, DW-1330 (Taiwan Resonant Waves Research Co., Taiwan R.O.C.), a prospective,&#xD;
      randomized, double-blinded trial is proposed. Investigators are going to recruit 60 patients&#xD;
      with non-specific low back pain for at least 3 months. Clinical assessments include Numerical&#xD;
      Rating Scale (NRS), Oswestry Disability Index (ODI), EuroQol instrument (EQ-5D), Pressure&#xD;
      pain threshold (PPT), and Heart rate variability (HRV). The 60 patients were double-blinded,&#xD;
      1:1:1-randomly-distributed into 3 groups using different variable-frequency combinations: (1)&#xD;
      Variable-frequency combination 1 (2) Variable-frequency combination 2 (3) Control(Placebo).&#xD;
      During the surveillance period, a total of 2 visits and a telephone follow-up is set at Time&#xD;
      point = 0, 2(telephone) and 4 week after recruitment. The primary endpoint is the change of&#xD;
      NRS. The secondary endpoint is change of Heart rate variability (HRV). The safety evaluated&#xD;
      index is the adverse event rate for all 3 groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of non-specific chronic low back pain scaled by numerical rating scale</measure>
    <time_frame>Time point = 0 week (before treatment), 2 week (during the treatment, by a telephone follow-up) and 4 week (after a 4-week treatment )</time_frame>
    <description>In a Numerical Rating Scale (NRS), patients are asked to circle the number between 0 and 10, 0 and 20 or 0 and 100 that fits best to their pain intensity [1]. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Heart rate variability</measure>
    <time_frame>Time point = 0 week (before treatment) and 4 week (after a 4-week treatment )</time_frame>
    <description>standard deviation of the normal-to-normal QRS interval (SDNN)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse rate</measure>
    <time_frame>Time period during 4-week treatment</time_frame>
    <description>Any adverse event accompany with the treatment will be document</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Specific Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Variable-frequency combination 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non disclosure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Variable-frequency combination 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non disclosure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-disclosure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy</intervention_name>
    <description>Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)</description>
    <arm_group_label>Control (Placebo)</arm_group_label>
    <arm_group_label>Variable-frequency combination 1</arm_group_label>
    <arm_group_label>Variable-frequency combination 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 20-80 years old, male or female.&#xD;
&#xD;
          2. Cases with normal psychological and communication functions who can cooperate with our&#xD;
             study.&#xD;
&#xD;
          3. Cases who are willing to sign permits and cooperate with our study including follow up&#xD;
             and examination.&#xD;
&#xD;
          4. Cases with complete clinical data and willing to accept investigation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cases who diagnose pregnancy within 12 months before included.&#xD;
&#xD;
          2. Cases who diagnose with malignant disease.&#xD;
&#xD;
          3. Cases with a history of epilepsy.&#xD;
&#xD;
          4. Cases who diagnose with fracture without fixation.&#xD;
&#xD;
          5. Cases who diagnose with impaired sensation or psychological function.&#xD;
&#xD;
          6. Cases whose skin condition is not feasible to accept treatment.&#xD;
&#xD;
          7. Cases with pacemaker.&#xD;
&#xD;
          8. Cases who allergic to the conductive medium&#xD;
&#xD;
          9. Cases with a major psychiatric disorder such as schizophrenia or bipolar disorder.&#xD;
&#xD;
         10. Cases with severe visual or auditory disorder.&#xD;
&#xD;
         11. Cases who cannot communicate with the Mandarin language.&#xD;
&#xD;
         12. Other mental diseases are not suitable assessed by the PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiunn-Horng Kang, Ph.D, MD</last_name>
    <phone>+886970405337</phone>
    <email>jhk@tmu.edu.tw</email>
  </overall_contact>
  <results_reference>
    <citation>Gozani SN. Fixed-site high-frequency transcutaneous electrical nerve stimulation for treatment of chronic low back and lower extremity pain. J Pain Res. 2016 Jun 28;9:469-79. doi: 10.2147/JPR.S111035. eCollection 2016.</citation>
    <PMID>27418854</PMID>
  </results_reference>
  <results_reference>
    <citation>Hazime FA, de Freitas DG, Monteiro RL, Maretto RL, Carvalho NA, Hasue RH, Jo√£o SM. Analgesic efficacy of cerebral and peripheral electrical stimulation in chronic nonspecific low back pain: a randomized, double-blind, factorial clinical trial. BMC Musculoskelet Disord. 2015 Jan 31;16:7. doi: 10.1186/s12891-015-0461-1.</citation>
    <PMID>25636503</PMID>
  </results_reference>
  <results_reference>
    <citation>Gozani SN, Ferree TC, Moynihan M, Kong X. Impact of transcutaneous electrical nerve stimulation on sleep in chronic low back pain: a real-world retrospective cohort study. J Pain Res. 2019 Feb 25;12:743-752. doi: 10.2147/JPR.S196129. eCollection 2019.</citation>
    <PMID>30881088</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcutaneous electrical nerve stimulation</keyword>
  <keyword>non specific chronic low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

